Dysplasia Clinical Trial
Official title:
A Phase I Study of Erlotinib in Patients With Premalignant Lesions of the Lung
This phase I trial studies the side effects and best dose of erlotinib hydrochloride in preventing cancer in patients with precancerous lesions of the lung. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Status | Terminated |
Enrollment | 60 |
Est. completion date | June 2013 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years to 79 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of a premalignant lung lesion (metaplasia or dysplasia) on autofluorescent bronchoscopy (AFB) within 1 month - Participants must have a >= 10 pack year lifetime smoking history; current and former smokers only are eligible for this trial - No contraindications for treatment with erlotinib or additional bronchoscopies - Absolute neutrophil count (ANC) of >= 1.5 x 10^9/L - Platelet count of >= 100 x 10^9/L - Creatinine level of less than 1.5 mg/dL - Total bilirubin =< 2.0 mg/dl - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN) - Alkaline phosphatase =< 2.5 x ULN - Must meet Eastern Cooperative Oncology Group (ECOG) performance status criteria of 0-1 - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) throughout the duration of the study and for 1 month following cessation of study drug; females must begin adequate contraception immediately following screening pregnancy test; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately; if she is pregnant, she will be immediately withdrawn from the study - Ability to understand and the willingness to sign a written institutional review board (IRB) approved informed consent document Exclusion Criteria: - Subjects with life-threatening medical conditions that would preclude the treatment intervention and bronchoscopy, including, but not limited to, unstable pulmonary function, acute cardiac failure, which is unstable despite medication use; uncontrolled hypertension; uncontrolled diabetes mellitus; unstable coronary artery disease; acute or chronic liver disease, ongoing or active infection; or psychiatric illness/social situations that would limit compliance with study requirements - Participants with evidence of an active cancer or carcinoma in situ, are not eligible - Participants currently taking medications that induce or inhibit the cytochrome P450, family 3, subfamily A, polypeptide 4-7 (CYP3A4-7) enzymes - Participants may not be receiving any other investigational agents within 3 months - Participants taking warfarin - History of allergic reactions attributed to erlotinib, a known hypersensitivity to erlotinib, or agents with a similar chemical or biological composition to erlotinib - Women who are pregnant or lactating are excluded from the study because based on the proposed mechanism of tyrosine kinase inhibition of erlotinib; erlotinib should be assumed to cause fetal harm when administered to a pregnant woman; there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with erlotinib - History of interstitial lung disease (ILD) |
Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | Boston University School of Medicine | Boston | Massachusetts |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | Northwestern University | Chicago | Illinois |
United States | University of Chicago Comprehensive Cancer Center | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | PK/PD parameters | Up to 90 days | No | |
Other | Pharmacogenomic profile | Up to 90 days | No | |
Primary | Change in the ratio of p-EGFR to total EGFR | Baseline up to 90 days | No | |
Secondary | Change in the expression of p-Akt | Analyzed using an analysis-of-variance (ANOVA) on the change from baseline expression level with a factor for dose (75, 50, 25 or 100). All tests will be two-sided and tested at level alpha=0.05. If the overall comparison is significant, pairwise comparisons will be done using straight Bonferroni adjustments. | Baseline up to 90 days | No |
Secondary | Change in the expression of p-Erk | Analyzed using an ANOVA on the change from baseline expression level with a factor for dose (75, 50, 25 or 100). All tests will be two-sided and tested at level alpha=0.05. If the overall comparison is significant, pairwise comparisons will be done using straight Bonferroni adjustments. | Baseline up to 90 days | No |
Secondary | Change in the expression of Ki67 | Analyzed using an ANOVA on the change from baseline expression level with a factor for dose (75, 50, 25 or 100). All tests will be two-sided and tested at level alpha=0.05. If the overall comparison is significant, pairwise comparisons will be done using straight Bonferroni adjustments. | Baseline up to 90 days | No |
Secondary | Incidence of toxicities, graded according to Common Toxicity Criteria, version 3.0 | Up to 30 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
Completed |
NCT05161013 -
A Proof-of-Concept Study Evaluating LINFU™
|
N/A | |
Completed |
NCT04072913 -
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix
|
N/A | |
Completed |
NCT04067778 -
IBD Neoplasia Surveillance Pilot RCT
|
N/A | |
Recruiting |
NCT06281392 -
Artificial Intelligence and Dysplasia Detection in Inflammatory Bowel Disease (EIIDISIA Study)
|
N/A | |
Completed |
NCT05171634 -
Artificial Intelligence and Dysplasia Detection in Ulcerative Colitis (CUDISIA Study)
|
N/A | |
Recruiting |
NCT06430372 -
Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract
|
Phase 1 | |
Active, not recruiting |
NCT02790853 -
Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders
|
Early Phase 1 | |
Recruiting |
NCT04867590 -
A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus
|
N/A | |
Completed |
NCT02075905 -
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
|
N/A | |
Completed |
NCT01140178 -
A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx
|
Phase 1 | |
Terminated |
NCT02481687 -
The Value of I-Scan and Confocal Laser Endomicroscopy for the Assessment of Chronic Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT01799200 -
Hip Pathomorphology in Collegiate Athletes and Controls
|
N/A | |
Recruiting |
NCT04054713 -
Acetic Acid for the Detection of Esophageal Neoplasms
|
N/A | |
Completed |
NCT03268993 -
Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT01816438 -
A French Non Interventional Multicentric Cohort Study in Patients With Colorectal Dysplasia
|
||
Terminated |
NCT00358111 -
Study of LUMA Cervical Imaging System as Adjunct to Colposcopy
|
Phase 4 | |
Active, not recruiting |
NCT01688908 -
Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)
|
N/A | |
Completed |
NCT02100189 -
Esophageal Cytology With FISH in Detecting Esophageal Cancer
|
N/A |